JP2015506948A - 組換え毒素を含むクロストリジウム・ディフィシレに対するワクチン - Google Patents

組換え毒素を含むクロストリジウム・ディフィシレに対するワクチン Download PDF

Info

Publication number
JP2015506948A
JP2015506948A JP2014554865A JP2014554865A JP2015506948A JP 2015506948 A JP2015506948 A JP 2015506948A JP 2014554865 A JP2014554865 A JP 2014554865A JP 2014554865 A JP2014554865 A JP 2014554865A JP 2015506948 A JP2015506948 A JP 2015506948A
Authority
JP
Japan
Prior art keywords
protein
seq
tcda
cdta
tcdb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014554865A
Other languages
English (en)
Japanese (ja)
Inventor
ヘインリツチズ，ジヨン・ヘンリー
ボドマー，ジーン−ルク
セコア，スーザン・リン
ゴーク，アーロン・ルデイー
キヤロアグイラー，イベツト
ジエンテイル，マリー−ピエール
ホートン，メラニー，エス
ミーゼイーウスキー，マシユー・ライアン
スキンナー，ジユリー，エム
ソンダーマイヤー，パウルス・ヤコブス・アントニウス
サブラマニアン，シヤムスンダー
ヘイイデンリエフケンス，カリン・フベルデイナ・アントニア・バン・デル
ワン，スー
シー，ジーンフー
ソコノスル，レイチエル・フローラ
ゾーマン，ジユリー，ケイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2015506948A publication Critical patent/JP2015506948A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014554865A 2012-01-27 2013-01-25 組換え毒素を含むクロストリジウム・ディフィシレに対するワクチン Pending JP2015506948A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261591631P 2012-01-27 2012-01-27
US61/591,631 2012-01-27
US201261596419P 2012-02-08 2012-02-08
US61/596,419 2012-02-08
US201261703754P 2012-09-20 2012-09-20
US61/703,754 2012-09-20
PCT/US2013/023189 WO2013112867A1 (en) 2012-01-27 2013-01-25 Vaccines against clostridium difficile comprising recombinant toxins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017026031A Division JP2017141226A (ja) 2012-01-27 2017-02-15 組換え毒素を含むクロストリジウム・ディフィシレに対するワクチン

Publications (1)

Publication Number Publication Date
JP2015506948A true JP2015506948A (ja) 2015-03-05

Family

ID=48873956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014554865A Pending JP2015506948A (ja) 2012-01-27 2013-01-25 組換え毒素を含むクロストリジウム・ディフィシレに対するワクチン
JP2017026031A Pending JP2017141226A (ja) 2012-01-27 2017-02-15 組換え毒素を含むクロストリジウム・ディフィシレに対するワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017026031A Pending JP2017141226A (ja) 2012-01-27 2017-02-15 組換え毒素を含むクロストリジウム・ディフィシレに対するワクチン

Country Status (14)

Country Link
US (1) US9388394B2 (cg-RX-API-DMAC7.html)
EP (1) EP2807186A4 (cg-RX-API-DMAC7.html)
JP (2) JP2015506948A (cg-RX-API-DMAC7.html)
KR (1) KR20140117433A (cg-RX-API-DMAC7.html)
CN (1) CN104039816B (cg-RX-API-DMAC7.html)
AR (1) AR089797A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013211973B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014018432A8 (cg-RX-API-DMAC7.html)
CA (1) CA2856443A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04187A (cg-RX-API-DMAC7.html)
MX (1) MX351074B (cg-RX-API-DMAC7.html)
RU (1) RU2014134365A (cg-RX-API-DMAC7.html)
TW (1) TW201335178A (cg-RX-API-DMAC7.html)
WO (1) WO2013112867A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504993A (ja) * 2012-12-23 2016-02-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃ．ディフィシルＣＤＴｂ及び／又はＣＤＴａタンパク質のエレメントを含む免疫原性組成物
JP2020509770A (ja) * 2017-03-15 2020-04-02 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2968629T3 (es) 2011-04-22 2024-05-13 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
JP6084631B2 (ja) * 2011-12-08 2017-02-22 ノバルティス アーゲー Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP2016518374A (ja) * 2013-04-22 2016-06-23 ボード オブ リージェンツ オブ ザ ユニバーシテイ オブ オクラホマ クロストリジウム・ディフィシルワクチン及び使用方法
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
EP3007724B1 (en) 2013-06-14 2023-07-05 Sanofi Pasteur Inc. Compositions and methods of immunizing against c. difficile
LT3160500T (lt) * 2014-06-25 2019-10-25 Glaxosmithkline Biologicals Sa Clostridium difficile imunogeninė kompozicija
JP2017212882A (ja) * 2014-10-10 2017-12-07 学校法人 名城大学 アセチルエステラーゼ及びその利用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20180110849A1 (en) 2015-05-15 2018-04-26 Sanofi Pasteur, Inc. Methods for immunizing against clostridium difficile
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
US11969461B2 (en) 2016-03-02 2024-04-30 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US12071666B2 (en) * 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
MX388528B (es) * 2017-06-09 2025-03-20 Hipra Scient S L U Vacuna que comprende toxoides de clostridium.
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
WO2020078420A1 (en) * 2018-10-17 2020-04-23 Eternity Biomedical Laboratories, Inc. Immunogenic preparations and methods against clostridium difficile infection
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途
JP2023134918A (ja) * 2022-03-15 2023-09-28 株式会社荏原製作所 研磨方法および研磨装置
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
US20110053244A1 (en) * 2009-08-27 2011-03-03 Oyler George A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
WO2011068953A2 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
US20120070859A1 (en) * 2010-09-17 2012-03-22 The Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant clostridium difficile toxin b
WO2012143902A1 (en) * 2011-04-22 2012-10-26 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
US7226597B2 (en) 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
EP1699814A4 (en) 2003-12-08 2009-01-14 Hybridon Inc MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF COMPOUNDS FORMED FROM SMALL OLIGONUCLEOTIDES
PT1766093E (pt) 2004-02-06 2011-08-24 Univ Massachusetts Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2004220B1 (en) * 2006-03-30 2015-07-01 Embrex Inc. Methods and compositions for vaccination of poultry
DK2396652T3 (da) * 2009-02-11 2018-01-29 Cedars Sinai Medical Center Diagnose af inflammatorisk tarmsyndrom baseret på cytoletalt udspilende toksin
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
DK2753352T4 (da) 2010-09-03 2022-09-12 Valneva Austria Gmbh Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
US20110053244A1 (en) * 2009-08-27 2011-03-03 Oyler George A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
WO2011068953A2 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
US20120070859A1 (en) * 2010-09-17 2012-03-22 The Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant clostridium difficile toxin b
WO2012143902A1 (en) * 2011-04-22 2012-10-26 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARTH, H. ET AL., MICROBIOL. MOL. BIOL. REV., vol. 68, JPN6016043794, 2004, pages 373 - 402, ISSN: 0003439820 *
BUSCH, C. ET AL., J. BIOL. CHEM., vol. 273, JPN6016043788, 1998, pages 19566 - 19572, ISSN: 0003439818 *
EGERER, M. ET AL., J. BIOL. CHEM., vol. 282, no. 35, JPN6016043783, 2007, pages 25314 - 25321, ISSN: 0003439815 *
GULKE, I. ET AL., INFECT. IMMUN., vol. 69, JPN6016043785, 2001, pages 6004 - 6011, ISSN: 0003439816 *
JANK, T. ET AL., J. BIOL. CHEM., vol. 282, JPN6016043782, 2007, pages 35222 - 35231, ISSN: 0003439814 *
VOTH, D.E. AND BALLARD, J.D., CLIN. MICROBIOL. REV., vol. 18, JPN6016043787, 2005, pages 247 - 263, ISSN: 0003439817 *
WANG, H. ET AL., INFECT. IMMUN., vol. 80, JPN6016043791, 12 May 2012 (2012-05-12), pages 2678 - 2688, ISSN: 0003439819 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504993A (ja) * 2012-12-23 2016-02-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃ．ディフィシルＣＤＴｂ及び／又はＣＤＴａタンパク質のエレメントを含む免疫原性組成物
JP2020509770A (ja) * 2017-03-15 2020-04-02 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
JP7149285B2 (ja) 2017-03-15 2022-10-06 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
JP2022179543A (ja) * 2017-03-15 2022-12-02 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
JP7397145B2 (ja) 2017-03-15 2023-12-12 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
US11938179B2 (en) 2017-03-15 2024-03-26 Novavax, Inc. Methods and compositions for inducing immune responses against Clostridium difficile

Also Published As

Publication number Publication date
CA2856443A1 (en) 2013-08-01
CN104039816A (zh) 2014-09-10
AR089797A1 (es) 2014-09-17
MX2014009106A (es) 2014-11-10
JP2017141226A (ja) 2017-08-17
MX351074B (es) 2017-09-28
BR112014018432A8 (pt) 2017-07-11
AU2013211973A1 (en) 2014-06-12
CN104039816B (zh) 2018-02-09
AU2013211973B2 (en) 2017-10-12
US20150044250A1 (en) 2015-02-12
KR20140117433A (ko) 2014-10-07
US9388394B2 (en) 2016-07-12
EP2807186A4 (en) 2016-01-27
BR112014018432A2 (cg-RX-API-DMAC7.html) 2017-06-20
EP2807186A1 (en) 2014-12-03
IN2014CN04187A (cg-RX-API-DMAC7.html) 2015-07-17
TW201335178A (zh) 2013-09-01
WO2013112867A1 (en) 2013-08-01
RU2014134365A (ru) 2016-03-20

Similar Documents

Publication Publication Date Title
US9388394B2 (en) Vaccines against clostridium difficile comprising recombinant toxins
US11357844B2 (en) Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
KR101667837B1 (ko) 돌연변이체 클로스트리듐 디피실레 독소에 관련된 조성물 및 그의 방법
KR101940939B1 (ko) 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
Tian et al. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models
CN111479821B (zh) 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台
CN117957016A (zh) Sars-cov-2与流感联合疫苗
US12331083B2 (en) Immunogenic compositions to treat and prevent microbial infections
KR20140101835A (ko) 클로스트리듐 디피실레 톡신-기반 백신
TWI605056B (zh) 用於治療艱難梭狀芽孢桿菌（Clostridium difficile）相關疾病之組成物及方法
US9102742B2 (en) Serologic correlates of protection against Bacillus anthracis infection
US20250304627A1 (en) Immunogenic Compositions to Treat and Prevent Microbial Infections
US20230310568A1 (en) Engineered arenavirus glycoprotein compositions and methods of use thereof
RU2773880C1 (ru) Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
TW202313660A (zh) 變異的金黃色葡萄球菌ＬｕｋＡ和ＬｕｋＢ多肽和疫苗組合物
CN117355328A (zh) 金黄色葡萄球菌疫苗组合物
EA049373B1 (ru) Варианты полипептидов luka и lukb staphylococcus aureus и вакцинные композиции

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170620